About us
BlueGnome was founded in Cambridge, UK, in 2002 by a team of
scientists who developed a novel mathematical technology for the
analysis of genetic data following the sequencing of the human genome in
2000.
With the support of the University of Cambridge and the
Wellcome Trust, BlueGnome went on to assemble a world class team of
mathematicians, biologists and software engineers with the aim of
developing a range of molecular tests which used these advances to
improve human health.
In February 2006 BlueGnome released the
CytoChip, a powerful new approach for the investigation of genetic
abnormalities. The CytoChip is now used in over 40 countries world wide.
Since 2006 over 50,000 samples have been investigated using the
CytoChip, mainly associated with developmental delay or with complex
leukaemias. The CytoChip is now used in over 200 labs as a first line cytogenetic test, replacing traditional G-band karyotyping.
In 2008 BlueGnome applied its unique combination of
technology and expertise to the problem of counting the chromosomes in a
single human cell. In collaboration with some of the world’s leading
IVF centres, BlueGnome developed 24sure and as part of a consented study
in September 2009 the first 24sure baby, Oliver, was born in the UK. 24sure is currently being used in ESHRE's preimplantation genetic screening RCT trial (June 2011).
BlueGnome
is privately held, profitable and has been included in the Deloite Fast 50 for the third year running, recently ranked the 2nd fastest growing biotech company in the UK with over 85% of sales going for export to major
laboratories around the world.
|
 |